Products
Brodalumab was approved in Japan in 2016 (Lumicef) and in the United States and EU in 2017 as a solution for injection (Siliq, Kyntheum).
Structure and properties
Brodalumab is an IgG2κ monoclonal antibody with a molecular weight of 144 kDa, consisting of 1312 amino acids. It is produced by biotechnological methods.
Effects
Brodalumab (ATC L04AC12) has anti-inflammatory and selective immunosuppressive properties. The effects are based on binding to the human interleukin-17 receptor A (IL-17RA). This inhibits interaction with the proinflammatory cytokines IL-17A, IL-17F, IL-17C, IL-17A/F, and IL-25.
Indications
For the treatment of plaque psoriasis.
Dosage
According to the SmPC. The drug is injected subcutaneously.
Contraindications
Brodalumab is contraindicated in hypersensitivity and in Crohn’s disease. For complete precautions, see the drug label.
Interactions
Live vaccines should not be administered during therapy and indirect interference with CYP450 isoenzymes is possible.
Adverse effects
The most common possible adverse effects include joint pain, headache, fatigue, diarrhea, and pain in the mouth and throat.
